In Vitro Evaluation of the Inhibitory Effect of Topical Ophthalmic Agents on Acanthamoeba Viability by Heaselgrave, W. et al.
In vitro evaluation of the inhibitory effect of topical ophthalmic agents  1 
on Acanthamoeba viability 2 
 3 
 4 
WAYNE HEASELGRAVE
1*
, ANAS HAMAD
1,3
, STEVEN COLES
4
  5 
and SCOTT HAU
2
 6 
 7 
1
Dept of Biomedical Science & Physiology, University of Wolverhampton, UK 8 
 9 
2
Department of External Disease, NIHR Moorfields Clinical Research Facility, Moorfields 10 
Eye Hospital, UK 11 
 12 
3
Department of Biology, University of Anbar, Al-Ramadi, P.O. Box 55431, Iraq 13 
 14 
4
Faculty of Science & the Environment, University of Worcester, Worcester, WR2 6AJ, UK 15 
 16 
Running title: Topical medications on the viability of Acanthamoeba spp. 17 
Keywords: Keratitis, Treatment and Acanthamoeba spp. 18 
*
Corresponding author. Mailing address: 19 
 20 
Dept of Biomedical Science & Physiology, University of Wolverhampton 21 
MA Building, City Campus South, Wulfruna Street, Wolverhampton, WV1 1LY 22 
UK 23 
Tel: +44 (0)1902 32 2709     Email: w.heaselgrave@wlv.ac.uk 24 
 25 
 26 
 27 
ABSTRACT 28 
Purpose: To compare the antimicrobial effect of topical anaesthetics, antivirals, antibiotics, 29 
and biocides on the viability of Acanthamoeba cysts and trophozoites in vitro.  30 
Methods: Amoebicidal and cysticidal assays were performed against both trophozoites and 31 
cysts of A. castellanii (ATCC 50370) and A. polyphaga (ATCC 30461). Test agents included 32 
topical ophthalmic preparations of commonly anaesthetics, antivirals, antibiotics, and 33 
biocides. Organisms were exposed to serial two-fold dilutions of the test compounds in the 34 
wells of a microtitre plate to examine the effect on Acanthamoeba spp. In addition, the 35 
toxicity of each of the test compounds was determined against a mammalian cell line. 36 
Results: Proxymetacaine, oxybuprocaine and especially tetracaine were all toxic to the 37 
trophozoites and cysts of Acanthamoeba but lidocaine was well tolerated. The presence of 38 
benzalkonium chloride (BAC) preservative in levofloxacin caused a high level of toxicity to 39 
trophozoites and cysts. With the diamidines the presence of BAC in the propamidine drops was 40 
responsible for the activity against Acanthamoeba. Hexamidine drops without BAC showed 41 
good activity against trophozoites and the biguanides PHMB, chlorhexidine, alexidine and 42 
octenidine all showed excellent activity against trophozoites and cysts of both species. 43 
Conclusions: The anti-amoebic effect of BAC, povidone iodine and tetracaine are superior to 44 
the current diamidines and slightly inferior to the biguanides used in the treatment for 45 
Acanthamoeba keratitis.  46 
Translational Relevance: Ophthalmologists should be aware that certain topical anaesthetics 47 
and ophthalmic preparations containing BAC, prior to specimen sampling may affect the 48 
viability of Acanthamoeba in vivo, resulting in false negative results in diagnostic tests.  49 
 50 
INTRODUCTION 51 
Acanthamoeba is a genus of small free-living amoebae common to most soil and freshwater 52 
habitats.
1
 The organism has a life cycle of a feeding and replicating trophozoite which, in 53 
response to adverse conditions, can form a dormant cyst stage.
1
 Acanthamoeba spp. are 54 
opportunistic pathogens of humans causing a fatal granulomatous encephalitis (GAE) in the 55 
immunocompromised host and, more frequently, a potentially blinding keratitis in both non-56 
contact lens (CL) or CL wearers.  57 
 58 
Currently there are approximately 4.1 million contact lens wearers in the UK,
2
 and 59 
established independent risk factors for developing acanthamoeba keratitis (AK) in CL 60 
wearers include: exposure to tap water in home, 
3, 4
 swimming or bathing when wearing CL, 61 
4, 5
 poor lens hygiene 
4-6
, and the use of rigid CL in orthokeratology.
6
 Furthermore, previous 62 
outbreaks of AK in both the UK and USA and have been attributed to efficacy issue with 63 
certain contact lens disinfections system.
7, 8
  64 
 65 
Despite the sight threatening risk with AK, in most series, it accounts for less than 5% of all 66 
CL related microbial keratitis. The reported incidence rates in CL users are 1 to 2 per million 67 
in the USA to 17 to 20 per million in the UK.
4
 A recent study from a tertiary hospital in the 68 
UK reported a incidence rate of just 2.3% for Acanthamoeba over a 12-year period from over 69 
1500 keratitis cases.
9
 Due to the low number of patients with AK, many are diagnosed late 70 
due to initially being mis-diagnosed and treated for bacterial or other forms of keratitis such 71 
as fungal and herpes simplex keratitis.
4,10
 Late diagnosis of AK has a massive impact on 72 
prognosis and patients are more likely to develop poorer visual outcome, longer duration of 73 
treatment,  corneal perforation, and the requirement of penetrating keratoplasty.
10
 Current 74 
medical therapy for AK is unlicensed and involves the topical administration of a biguanide 75 
either 0.02% polyhexamethylene biguanide (PHMB) or 0.02% chlorhexidine, either as 76 
monotherapy or in combination with 0.1% propamidine or 0.1% hexamidine.
11
 PHMB and 77 
chlorhexidine have been reported to be the most effective and are effective against both 78 
trophozoites and cysts of Acanthamoeba. 
12-14
  79 
 80 
In the UK, diagnosis of AK is not standardised and depends largely upon individual clinics 81 
and hospitals. 
15
 A variety of methods can be employed with culture of a corneal scrape on 82 
2.5% non-nutrient agar which has been overlaid with a lawn of Escherichia coli, the most 83 
common method utilised and considered the gold standard. Despite the wide use of this 84 
culture-based method, poor sensitivity means that in many cases the culture comes back 85 
negative in patients with the infection. A recent study looking at diagnostic sensitivity 86 
reported a value of 33.3% for culture compared to 74.1% and 100% for polymerase chain 87 
reaction (PCR) and in vivo confocal microscopy, respectively.
16
   88 
 89 
One possibility for the low sensitivity of culture-based diagnostics for Acanthamoeba could 90 
be related to prior topical therapy such as anaesthetics and antibiotics applied to the cornea 91 
prior to the corneal scrape being performed on the patient. Goldschmidt et al have found that 92 
fluorescein and topical anaesthetics could interfere with real time PCR to detect herpes virus 93 
and Acanthamoeba resulting in false negative results.
17
 Other studies have also shown the use 94 
of Rose Bengal and Lissamine green reduced PCR detection rate for herpes virus and 95 
toxoplasma.
18
 Furthermore, empirical antibiotic treatment with fluoroquinolone drugs or 96 
other biocides prior to diagnosis could have an effect on the viability of Acanthamoeba. 97 
Aside from the antimicrobial drugs, many ophthalmic preparations utilise benzalkonium 98 
chloride (BAC) as a preservative and it has been shown BAC is highly toxic to 99 
Acanthamoeba.
19
 100 
 101 
Due to the potential effect of topical anaesthetics and antimicrobials on the viability of 102 
Acanthamoeba cysts and trophozoites, we studied the activity of a range of commonly used 103 
topical anaesthetics, antibiotics, antivirals and biocides against the trophozoite and cyst stage 104 
of A. polyphaga (ATCC 30461) and A. castellanii (ATCC 50370), and a mammalian cell line.  105 
 106 
MATERIALS AND METHODS 107 
Reagents and test compounds. 108 
We tested a range of ophthalmic preparations including biocides, diamidines, anaesthetics, 109 
antivirals and antibiotics. All agents were obtained from Sigma Chemical Company Ltd 110 
(Poole, UK) unless otherwise stated. The biocides, diamidines and miscellaneous compounds 111 
included Brolene
®
 (Propamidine isethionate 0.1% w/v, Sanofi, UK), Desomedine
®
 112 
(Hexamidine di-isetionate 0.1%, Bausch & Lomb, France), PHMB (Lonza, UK), octenidine 113 
(Schulke & Mayr, Germany), chlorhexidine digluconate 0.1% w/v, alexidine 0.1% w/v, 114 
propamidine 0.1% w/v, hexamidine 0.1% w/v pentamidine 0.1% w/v, BAC 0.1% w/v, 115 
phenylmercuric nitrate 0.1% w/v, fluorescein sodium 2% w/v (Minims, Bausch & Lomb, 116 
UK) and povidone iodine 5% w/v (Minims, Bausch & Lomb, UK). Antibiotics used were 117 
preserved levofloxacin 5 mg/ml (Oftaquix
®
, Santen, UK), preservative free levofloxacin 118 
5mg/ml (Oftaquix Unit Dose
®
, Santen, UK), moxifloxacin 0.5% w/v (Moxeza
®
, Novartis, 119 
UK), preserved chloramphenicol 0.5% w/v (Martindale Pharma, UK), and preservative free 120 
chloramphenicol 0.5% w/v (Minims, Bausch & Lomb, UK). The topical anaesthetics tested 121 
were all in MINIMS
®
 formulation (Bausch & Lomb, UK) and they included proxymetacaine 122 
(proparacaine) 0.5% w/v, tetracaine 1% w/v, oxybuprocaine 0.4% w/v, and lidocaine 4% w/v 123 
with fluorescein sodium 0.25% w/v. Antivirals used were trifluorothymidine 1% w/v 124 
(Stockport Pharmaceuticals, UK) and aciclovir 0.1% w/v. All the compounds were stored 125 
according to the manufacturers’ recommendations. 126 
 127 
 128 
 129 
Test organism strains and culture. 130 
A. castellanii (ATCC 50370) and A. polyphaga (ATCC 30461) were obtained from the 131 
American Type Culture Collection (LGC standards, Teddington, UK). Trophozoites were 132 
maintained in a semi-defined axenic broth medium as previously described.
20
 Cysts were 133 
produced using Neff’s encystment medium (NEM) method as previously described 20. 134 
Trophozoites were seeded into large tissue culture flasks (Nunc, UK) at a density of 1 x 10⁵ 135 
cells / ml in 50 ml of growth medium and incubated for 48 hours at 30C. The trophozoites 136 
were harvested by centrifugation at 500 x g for 5 minutes and washed three times with ¼ 137 
strength Ringer's solution. The final pellet was then inoculated into 50 mL of NEM at a 138 
density of 1 x 10
6 
cells / ml into tissue culture flasks. The cultures were then incubated at 139 
30C for 7 days on a shaking incubator. The cysts were harvested for testing after 7 days of 140 
incubation in NEM and washed three times with ¼ strength Ringer’s solution. The pellet was 141 
adjusted to 5 x 10⁶ cysts / ml using a modified Fuchs Rosenthal haemocytometer (Hawksley, 142 
UK) and the cysts stored at 4 to 8C for testing within 14 days. 143 
 144 
Amoebicidal assays.  145 
In the trophozoite assay, serial two-fold dilutions of the test compounds were made in the 146 
wells of a tissue culture grade microtitre plate (Helena Biosciences, Gateshead, UK).  147 
Ophthalmic preparation used straight from the bottle and serially diluted from the 148 
concentration stated on the product information label. Pure drugs were prepared as 1 mg/ml 149 
(0.1%) stock solution in an appropriate solvent. Control wells received ¼ strength Ringer’s 150 
solution in place of test solution. Log phase cultures of axenic trophozoites were adjusted to a 151 
concentration of 2 x 10
4
 /ml in growth medium and 100 µl of the calibrated suspension added 152 
to the wells for incubation at 30°C in triplicate. After 48 h, the wells were inspected using an 153 
inverted microscope. This was achieved by comparing the appearance of the trophozoites in 154 
the test wells to those in controls. Typically this involves visually comparing the degree of 155 
amoeba growth relative to the control as well as looking for cell lysis and rounding of the 156 
amoebae. The minimum trophozoite inhibitory concentration (MTIC) was defined as 50 % 157 
inhibition of Acanthamoeba trophozoite replication compared to the controls. The minimum 158 
trophozoite amoebicidal concentration (MTAC) was defined as the lowest concentration of 159 
test compound that resulted in the complete lysis or degeneration of the trophozoites. 160 
 161 
Cysticidal assays.  162 
The cysticidal assay relies on the observation that Acanthamoeba cysts adhere to the well 163 
bottoms of the microtitre plates and remain attached following exposure to the test compound 164 
and removal by washing. Addition of a live E. coli to the wells, followed by incubation, 165 
results in encystment of viable cysts and replication of the emergent trophozoites. Serial two-166 
fold dilutions of the test compounds were prepared with distilled water in the wells of the 167 
microtitre plate. Cysts were adjusted to a final concentration of 2 x 10
4
 cells / ml in ¼ 168 
strength Ringer's solution and 100 µl added to each well. The plates were then incubated at 169 
30°C for 48 hours. After incubation the wells were aspirated to remove the drug using a 170 
Vacusip (Integra, UK) and refilled with ¼ strength Ringer’s solution. This process was 171 
repeated three times to ensure removal of the drugs from the wells. After the final aspiration 172 
the wells were filled with 100 µl of ¼ strength Ringer's containing live E. coli (ATCC 8739) 173 
at an optical density of 0.2 at 540nm and incubated at 30°C. The minimum cysticidal 174 
concentration (MCC) was defined as the lowest concentration of test compound that resulted 175 
in no excystation and trophozoite replication after 7 days incubation. 176 
 177 
 178 
 179 
Hep-2 cell cytotoxicity.  180 
The cytotoxicity of the test compounds was determined against the Hep-2 (HeLa derivative) 181 
human cervix carcinoma cell line (ECACC #86030501) obtained from the European 182 
Collection of Cell Cultures (Centre for Applied Microbiology and Research, Salisbury, U.K). 183 
The cells were grown and maintained at 37°C in Minimum Essential Medium with 10% heat-184 
inactivated foetal bovine serum (Life Technologies Ltd, Paisley, Scotland). Flasks containing 185 
confluent monolayers of cells were used to seed a 96 well microtitre plate at a concentration 186 
of 1 x 10
4
 cells /well in 100 µl of growth medium with incubation at 37°C. Once 187 
approximately 75% confluent growth occurred in the wells, the medium was changed, and 188 
the cells used for cytotoxicity testing. Serial two-fold dilutions of the test agent in appropriate 189 
solvent were added to the wells and the plate incubated at 37°C for 24 hours. The degree of 190 
cytotoxicity was determined using the CellTiter 96 AQuous One Solution Cell Proliferation 191 
Assay (Promega, Southampton, U.K.). This is a colourmetric assay in which metabolically 192 
active cells bioreduce a tetrazolium compound to generate a soluble coloured formazan 193 
product whose abundance can be measured spectrophotometrically at 595nm 
21
. 194 
 195 
Transmission Electron Microscopy (TEM) of Acanthamoeba cysts  196 
For the TEM studies Neff’s cysts of A. castellanii were used. The cysts were exposed to the 197 
test formulations using either topical ophthalmic preparations (tetracaine 1% and preserved 198 
chloramphenicol 0.5%) or a solutions made up to the same concentration used in ophthalmic 199 
preparations (PHMB 0.02%, unpreserved chloramphenicol 0.5%, benzalkonium chloride 0.05 200 
mg/ml and povidone-iodine 5%). Controls cysts were exposed to 1/4 strength Ringer’s 201 
solution. The cysts were exposed to the test formulations at 32 °C for 1 hour. The agents were 202 
removed by washing the cysts with ¼ strength Ringer's solution and centrifuged at 1000 x g 203 
for 5 minutes. The resulting pellets were fixed with 2.5% (v/v) glutaraldehyde buffered with 204 
0.1M HEPES at pH 7.2 overnight at 4°C before being processed for TEM microscopy. 205 
 206 
RESULTS 207 
The activity of the test compounds against the trophozoites and cysts of A. castellanii (ATCC 208 
50370) and A. polyphaga (ATCC 30461) and their toxicity for Hep-2 cells is shown in Tables 209 
1-4.  210 
 211 
The results for the topical anaesthetics and fluorescein sodium are shown in Table 1. The 212 
inhibitory range against Acanthamoeba trophozoites for the anaesthetics proxymetacaine, 213 
tetracaine and oxybuprocaine were 9.75-39 µg/ml whereas lidocaine produced no inhibition 214 
of growth until the 312-625 µg/ml range for both species. In the trophozoite amoebicidal 215 
studies proxymetacaine, tetracaine and oxybuprocaine were amoebicidal in the 19.5-250 216 
µg/ml range whereas with lidocaine, the amoebicidal activity against A. polyphaga and A. 217 
castellanii was 312 and 1250 µg/ml, respectively. For the cyst assays, proxymetacaine, 218 
tetracaine and oxybuprocaine were cysticidal in the 39-250 µg/ml range. With lidocaine the 219 
cysticidal activity against A. polyphaga and A. castellanii was 1.25 and 10 mg/ml, 220 
respectively. In the toxicity assay against the mammalian cell line, proxymetacaine, tetracaine 221 
and oxybuprocaine were cytotoxic in the 39-156 µg/ml range whereas lidocaine produced no 222 
cytotoxicity until 5 mg/ml. The lidocaine MINIMS contain fluorescein sodium and so as a 223 
control this was tested separately and found to be non-toxic at the 2% concentration (Table 224 
1).   225 
 226 
 227 
 228 
The results for the topical antibiotics, antivirals and preservatives are shown in Table 2. For 229 
the fluoroquinolones, levofloxacin (Oftaquix
®
) formulation demonstrated trophozoite 230 
inhibitory and amoebicidal activity in the 78-312 µg/ml range whereas for the unpreserved 231 
levofloxacin (pure drug without BAC), the values were in the 312 to 1250 µg/ml range for 232 
both species, a factor of 4 difference in magnitude from the commercial ophthalmic 233 
preparation. Moxifloxacin (Moxeza
®
) demonstrated trophozoite inhibitory and amoebicidal 234 
activity in the 625-2500 µg/ml range for both species. Against cysts, levofloxacin 235 
(Oftaquix
®
) was cysticdal at 625 µg/ml compared to levofloxacin (pure drug) and 236 
moxifloxacin which showed cysticidal activity in the 2.5-5 mg/ml range. For the toxicity 237 
assay, levofloxacin (Oftaquix
®
) and moxifloxacin gave a toxicity of 39 and 156 µg/ml, 238 
respectively. Two preparation of the chloramphenicol were tested. The preserved and 239 
preservative free versions showed inhibitory activity against trophozoites at 39 to 312 µg/ml 240 
whereas for the cysts this ranged from 312 µg/ml to 2.5 mg/ml for the two species of 241 
Acanthamoeba, respectively. Phenylmercuric nitrate which is the preservative used in 242 
Chloramphenicol was active against trophozoites in the 1-3.9 µg/ml range and against cysts 243 
in the 15.6-31.3 µg/ml range. BAC which is commonly added to ophthalmic preparations as a 244 
preservative was active against trophozoites in the 1-7.8 µg/ml range and against cysts in the 245 
7.8-15.6. µg/ml range.  246 
 247 
The antiviral Trifluorothymidine (TFT) was active against trophozoites in the 312-1250 248 
µg/ml range and against cysts in the 2.5-5 mg/ml range. Aciclovir ophthalmic ointment 249 
(Zovirax
®
) could not be used due to the soft paraffin base and so a solution was prepared 250 
from pure drug. Aciclovir was active against trophozoites in the 63-250 µg/ml range but 251 
showed no activity against cysts in the range tested. 252 
 253 
The effect of the diamidines against Acanthamoeba trophozoites and cysts and the toxicity to 254 
the mammalian cell line is shown in Table 3. With hexamidine, the pure drug and the 255 
Desomedine
®
 formulation performed identically in all tests against both species and the 256 
mammalian cell line. With propamidine, the pure drug showed a trophozoite inhibitory effect 257 
in the 63-250 µg/ml range compared to 7.8-15.6 µg/ml range for the Brolene
®
 formulation. 258 
For the amoebicidal activities, propamidine (pure drug) was in the 250-500 µg/ml range 259 
compared to 15.6-31.3 µg/ml range for the Brolene® formulation. Both the pure drug and 260 
Brolene
®
 formulation showed limited to no activity against the cysts of both species. In the 261 
toxicity studies, the propamidine (pure drug) showed limited toxicity at 250 µg/ml compared 262 
to 31.3 µg/ml for the Brolene
®
 formulation. Pentamidine showed almost identical activity to 263 
that of propamidine. Comparatively, BAC was more effective than any of the diamidines 264 
tested showing activity against the trophozoites, cysts, and greater cytotoxicity to mammalian 265 
cells (Table 2).  266 
 267 
The effect of the biguanide compounds and povidone iodine against Acanthamoeba 268 
trophozoites and cysts, and the toxicity to the mammalian cell line is shown in Table 4. In the 269 
trophozoite assay all of the biguanides demonstrated inhibitory activity in the 0.5-1.95 µg/ml 270 
range and amoebicidal activity in the 1-15.6 µg/ml range. For cysticidal activity, the 271 
biguanides ranged from 3.9-31.3µg/ml; both octenidine and Alexidine were comparable to 272 
PHMB in terms of antimicrobial efficacy. For the toxicity assay, the biguanides ranged 273 
between 1-31.3 µg/ml with PHMB demonstrating the highest value (least cytotoxic). 274 
Povidone Iodine was active against trophozoites in the 7.8-31.3 µg/ml range and against cysts 275 
in the 7.8-15.6 µg/ml range.  276 
 277 
 278 
 279 
The changes in the morphology of the cysts when exposed to various compounds taken with 280 
TEM are shown in Figure 1. As a control, a healthy Neff’s cyst in ¼ strength Ringer’s 281 
solution can be seen in Figure 1A. The healthy cyst has a thick cyst wall surrounding the 282 
encysted trophozoite. The trophozoite plasma membrane touches the endocyst wall taking up 283 
the full space available inside the cyst. In the cytoplasm, the nucleus can clearly be seen as 284 
can the rounded structures including mitochondria and lysosomes.  285 
 286 
After exposure to tetracaine, the nucleus is no longer visible and the cytoplasm is full of 287 
micelles caused by the breakup of the nuclear membrane (Figure 1B). With preserved 288 
chloramphenicol, propamidine pure drug, and unpreserved chloramphenicol, no changes in 289 
intracellular organisation of the cytoplasm and nucleus were observed, respectively (Figure 290 
1C, D, and H). 291 
 292 
With BAC (0.05 mg/ml), the plasma membrane of the encysted trophozoite has been 293 
damaged and shrunk away from the walls of the endocyst and there is an lack of a defined 294 
nucleolus and an increase in the number of cytoplasmic micelles consistent with membrane 295 
damage (Figure 1E).  296 
 297 
With povidone iodine (5% w/v) and PHMB, the plasma membrane of the encysted 298 
trophozoite has been severely damaged and has shrunk significantly away from the walls of 299 
the endocyst. No defined nuclear structures were seen and there are large numbers of micellar 300 
aggregations inside the cyst suggesting complete plasma membrane destruction in the 301 
encysted trophozoite (Figure 1F and 1G).  302 
 303 
 304 
 305 
DISCUSSION 306 
AK is a sight-threatening corneal infection and early diagnosis is paramount in achieving a 307 
better prognosis and visual outcome. Risk factor determination and clinical examination can 308 
often differentiate AK from other forms of keratitis, with ring infiltrate or disease confined to 309 
the epithelium to be more common compared to bacterial and fungal keratitis.
22
  However, in 310 
epithelial disease, especially associated with dendritic-type lesions, Acanthamoeba can be 311 
misdiagnosed with other causes of keratitis such as herpes simplex (HSV) keratitis.
4,10 
312 
Traditionally, cultures have been the mainstay in diagnosing Acanthamoeba but a low culture 313 
positive rate and 
23
 prolonged incubation period, often lead to a delay in diagnosis and 314 
treatment.
24
 The use of IVCM and PCR in diagnosing AK have shown good promise with 315 
sensitivity values ranging between 56-100% 
25-28
 and 77-88%, respectively.
16, 29, 30
 The main 316 
advantages of IVCM are it is non-invasive and it provides a rapid diagnosis but the main 317 
limitations are the potential difficulty in differentiating pathogenic organisms from host cells, 318 
and the diagnostic accuracy is dependent on observer experience.
26
 PCR testing is quicker 319 
and more sensitive than culture, returning a result often within days rather than weeks but 320 
similar to cultures, false negative results do occur. Possible factors include the amount of 321 
viable acanthamoeba obtained from the corneal scrape or biopsy and inhibition effect from 322 
the use of topical agents before microbiological sampling such as prior empirical treatment 323 
with antibiotics, the use of anaesthetics and vital stains such as fluorescein.
17, 31
 There are 324 
limited data on the inhibitory effect of topical anaesthetics with one study showing 325 
proparacaine (proxymetacaine) did not adversely affect PCR 
31
 whereas in a second study,
17
 326 
they found oxybuprocaine inhibited real-time PCR in detecting Acanthamoeba. We have 327 
found the type of topical anaesthetic greatly affected the viability of Acanthamoeba in that 328 
lidocaine had a much lower antimicrobial effect and at therapeutic concentration, it did not 329 
exert significant antimicrobial activity against cysts and trophozoites for two species of 330 
Acanthamoeba. Although the lidocaine used in this study was combined with fluorescein, we 331 
did not find testing fluorescein on its own, had any major antimicrobial effect on the 332 
trophozoites or cysts. This contrasts with the other topical anaesthetics, in particular 333 
tetracaine which was observed to exert a much stronger antimicrobial effect against 334 
trophozoites, cysts of Acanthamoeba and toxicity to a human cell line. The antimicrobial 335 
effect of proxymetacaine was similar to oxybuprocaine for A. castellanii but for A. 336 
polyphaga, proxymetacaine had a greater amoebicidal and cysticidal effect, in addition to 337 
being more toxic to the human cell line. These results suggest the use of topical anaesthetics, 338 
especially with tetracaine, can have potent anti-amoebic effect and it may be an important 339 
contributory factor in the reported low sensitivity for culture from corneal scrape.   340 
 341 
Depending on antibiotics protocol used, empirical treatment with a third or fourth generation 342 
fluoroquinolones, due to their broad-spectrum antimicrobial activity, is often prescribed as an 343 
initial therapy for the treatment of microbial keratitis.
32
 We found the pure drug of 344 
levofloxacin and a preservative free preparation of moxifloxacin (Moxeza
®
) did not exert any 345 
major antimicrobial effect on the viability of Acanthamoeba whereas for preserved 346 
levofloxacin (Oftaquix
®
), which is preserved with BAC, had a much greater antimicrobial 347 
activity on both species of Acanthamoeba. This indicates it is the BAC in preserved 348 
levofloxacin rather than the drug itself that is causing the antimicrobial effect observed. 349 
Thompson and co-workers did not find any adverse effect on PCR amplification for 350 
Acanthamoeba with gatifloxacin or moxifloxacin.
31
 The gatifloxacin used in their study 351 
(Zymar; Allergan, Irvine, CA) was preserved with BAC whereas the moxifloxacin was self-352 
preserved. Although they did not test BAC on its own, the minimal inhibitory effect found 353 
with both antibiotics suggests the effect of BAC on PCR in detecting Acanthamoeba DNA 354 
may be less compared to the amoebicidal and cysticidal assay methods used in this study. 355 
Comparing the two preparations of chloramphenicol, the preserved drug had a much higher in 356 
vitro activity against Acanthamoeba suggesting the anti-amoebic effect is related to the 357 
preservative phenylmercuric nitrate. That said, the TEM images did not show much 358 
difference in the morphology with the preserved and preservative free version of 359 
chloramphenicol.  360 
This difference in anti-amoebic activity was also seen when comparing preserved 361 
propamidine (Brolene
®
), a common over the counter (OTC) ant-infective ophthalmic 362 
preparation in the UK, with the pure drug propamidine. Previously, it has been shown that the 363 
concentrations of BAC typically found in ophthalmic medicines are highly toxic to 364 
Acanthamoeba trophozoites. In the study by Tu et al, exposing trophozoites to BAC 365 
concentrations in the 10-30 µg/ml range, produced up to a 4.5 log reduction in viability over 366 
6.5 hours.
19
 However, this present study is the first to observe the effect of BAC containing 367 
preparations against the highly resistant cystic stage of Acanthamoeba. We found the MTIC, 368 
MTAC and MCC for BAC was significantly lower than the concentration of the BAC present 369 
in both Brolene
®
 (50 µg/ml) and Oftaquix
®
 (50 µg/ml) ophthalmic preparations. Indeed, this 370 
study has demonstrated that the presence of the BAC preservative in propamidine (Brolene
®
) 371 
eye drops is likely to be solely responsible for the observed anti-amoebic activity. Two 372 
previous studies have reported MTAC values for propamidine of 5-25 µg/ml and 0.49-0.97 373 
µg/ml but in both studies they only used the benzalkonium preserved Brolene
®
 without 374 
comparing it to propamidine pure drug.
33, 34
 This is the first study that has compared 375 
propamidine (pure drug) against BAC preserved propamidine (Brolene
®
), and we found the 376 
MTAC range for Brolene
®
 (15.6-31.3 µg/ml) to be similar to the study found by Hay et al 377 
and higher than the values found in the study by Elder  et al.  However, when tested in the 378 
absence of BAC, the MTAC was much higher in the 250-500 µg/ml range (Table 2). This 379 
confirms that the anti-amoebic activity of Brolene
®
 is down to the presence of BAC in the 380 
formulation. In fact, the amount of BAC in Brolene
®
 (50 µg/ml) is much higher than the 381 
MTAC found in this study, typically12.8 times greater than the concentration observed to 382 
inhibit trophozoites. Morphologically, the TEM images shown clear evidence that BAC 383 
causes damage to the cysts and this is in agreement with the findings from Sunada et al who 384 
found destruction of the cytoplasmic elements and separation of the inner and outer walls 385 
when cysts were exposed to BAC.
36
 However, in their study, the TEM cyst images with BAC 386 
and propamidine showed similar level of destruction of encysted trophozoite and this is due 387 
to the fact that the authors did not use pure propamidine and instead they used GoldenEye
® 
388 
eye drops which contain 0.1% w/v propamidine preserved with 0.05% benzalkonium 389 
chloride.  390 
 391 
Many multi-dose ophthalmic preparations utilise BAC as a preservative to prevent 392 
contamination of the formulation, therefore, the empirical use of BAC preserved eye drops 393 
prior to a diagnosis of AK is likely to have a negative impact on the viability of 394 
Acanthamoeba present on the cornea, which may further contribute to the reported low 395 
positive culture rate for AK from corneal scrapes. Aciclovir demonstrated greater inhibitory 396 
and amoebicidal effect on trophozoites compared to trifluorothymidine but neither drug 397 
appeared to be effective against the cysts. Aciclovir is commonly used to treat HSV keratitis 398 
and as AK is often misdiagnosed as HSV, the potential inhibitory effect on 399 
Acanthamoeba.trophozoites would need to be considered.  400 
 401 
When the experiments were repeated with hexamidine (Desomedine
®
), another diamidine 402 
commonly used in the treatment of AK, we found that this gave identical results to 403 
hexamidine (pure drug). This result is not surprising as Desomedine
®
, unlike Brolene
®
, does 404 
not contain any preservatives. Moreover, this study has examined the activity of three 405 
different diamidines with increasing alkyl chain lengths between the aromatic benzene rings. 406 
The observation that the 6 carbon hexyl chain length compound hexamidine has superior 407 
activity to the propyl and pentyl diamidines, is consistent with a previous study in that 408 
diamidine anti-amoebic activity increases with lipophilicity due to increased interaction with 409 
the Acanthamoeba lipid bilayer.
35
   410 
 411 
The aim of this study was to assess the potential inhibitory effect of prior administration of 412 
commonly used topical agents on the viability of Acanthamoeba before microbiological 413 
sampling but to obtain a sense of how potent these agents are, we also compared the in vitro 414 
susceptibility to current and potential new treatment for AK. The results obtained in this 415 
study for chlorhexidine and PHMB are consistent with previous published studies, with 416 
PHMB demonstrating superior activity to chlorhexidine.
31, 36
 The standard topical PHMB 417 
used in treating AK is 0.02% (200 µg/ml) which is nearly 20 times the mean MCC for PHMB 418 
found in this study, the finding agrees with the general favourable in vitro sensitivities and 419 
clinical outcome with PHMB compared to other anti-amoebic drugs.
15
 However, Sunada et al 420 
did not find their Acanthamoeba isolates had high in vitro susceptibility to PHMB.
37
 421 
Furthermore, the TEM appearance of the cysts in this study seem to be more affected with 422 
damage to the cyst plasma membrane clearly seen compared to Sunada et al who found 423 
mainly a loss of electron-dense material in the cytoplasm.
36
 We found both alexidine and 424 
octenidine demonstrated very good in vitro sensitivities and in fact octenidine was superior to 425 
PHMB for MTAC and MCC for both species of Acanthamoeba, though toxicity against 426 
mammalian cell line was comparatively higher. This is the first study that has reported the 427 
activity of octenidine against Acanthamoeba cysts and trophozoites. The results of this study 428 
on alexidine agree with a previous study which reported an MTAC of 10 µg/ml although they 429 
observed a much higher MCC (100 µg/ml).
38
 The exact reason for this difference is unclear 430 
but the concentration of cysts used in the Alizadeh et al study was 100-fold greater at 1 x 10
6
 431 
compared to 1 x 10
4
 / ml used in this and other published studies. Neither alexidine and 432 
octenidine are currently used to treat AK in a clinical setting but the favourable antimicrobial 433 
activity against both Acanthamoeba cysts and trophozoites, especially with octenidine, 434 
warrants further investigation as they may be useful in patients who do not respond to 435 
standard antiamoebic treatment. Alexidine, at a concentration of 1.6 µg/ml, is incorporated in 436 
one contact lens solution (AMO
®
 RevitaLens OcuTec) and it has been demonstrated that 437 
alexidine has excellent activity against cysts of Acanthamoeba.
39
 Aside from Alexidine, the 438 
majority of the multi-purpose contact lens solutions (MPS) utilises PHMB alone or in 439 
conjunction with polyquaternium-1. The concentration of PHMB containing MPS are in the 440 
order of 1 µg/ml, which is equivalent to the MTIC found in this study. Accordingly, the aim 441 
of these MPS is to provide effective disinfectant properties through the prevention and 442 
inhibition of pathogenic organisms on the contact lens or the contact lens case and therefore, 443 
it is possible that the release of the biocide from the contact lens can exert and inhibitory 444 
effect on the viability of Acanthamoeba on the cornea. The uptake and release of biocides 445 
occurs in all types of contact lenses but the interaction is complex and varies with numerous 446 
factors, therefore the potential inhibitory effect on Acanthamoeba with the release of biocide 447 
from contact lenses on the cornea is currently unknown.          448 
 449 
We found povidone iodine, as in other studies, demonstrated good in vitro activity on 450 
Acanthamoeba isolates with clear signs of damage from the TEM images. In fact, the MCC 451 
activity was identical to PHMB and superior to both propamidine and hexamidine. Although 452 
povidone iodine is not routinely used prior to performing a cornea scrape, the potential 453 
inhibitory effect on the viability of Acanthamoeba must be bore in mind.    454 
 455 
The main limitation of this study is findings from in vitro sensitivities do not always correlate 456 
with clinical outcome.
15
 There are many factors to explain this. The cysticidal assay exposed 457 
the cysts to the testing compound and then re-examined in 7 days for excystation and 458 
trophozoite replication. In a clinical setting, corneal scrape for culture is performed straight 459 
after the instillation of topical anaesthetics or vital stain, therefore, a shorter assay period 460 
would be more representative. Although we tested two commonly used fluoroquinolones and 461 
chloramphenicol, prior empirical antimicrobial treatment for microbial keratitis varies with 462 
different institutions so the in vitro sensitivities might be different with different antibiotics. 463 
In addition, the interaction of the epithelium with a drug and the penetration of it into the 464 
stroma would be different with different type of drugs. These are shortcomings with in vitro 465 
sensitivity and efficacy studies of drugs on pathogens. Notwithstanding this, the potential 466 
adverse effect on the viability of Acanthamoeba with drugs used during clinical examination 467 
to reduce pain or the prior treatment with antibiotics before obtaining tissue specimens for 468 
culture or PCR has to be considered. 469 
                 470 
In conclusion, the present work indicates the use of proxymetacaine, oxybuprocaine and 471 
tetracaine to reduce pain, ophthalmic preparations containing preservatives such as BAC and 472 
the use of povidone iodine, prior to specimen sampling, may affect the viability of 473 
Acanthamoeba in vivo, resulting in reduce culture yield and inhibition effect on PCR 474 
amplification.  475 
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Table 1. Efficacy of topical anaesthetics and fluorescein sodium against Acanthamoeba spp. 632 
trophozoites and cysts, and toxicity to a human epithelial cell line (Hep2). 633 
In vitro drug sensitivities (µg/ml) 
Drug 
A. castellanii A. polyphaga Hep2 
MTIC MTAC MCC MTIC MTAC MCC MCT 
 
Proxymetacaine 39 156 156 39 78 156 39 
Tetracaine 9.75 19.5 39 19.5 39 78 156 
Oxybuprocaine 31.3 250 125 15.6 125 250 125 
Lidocaine (+Fluorescein) 312 1250 10000 625 312 1250 5000 
Fluorescein sodium (2%) >10000 >10000 >10000 >10000 >10000 >10000 1250 
MTIC = minimum trophozoite inhibitory concentration, MTAC = minimum trophozoite 634 
amoebicidal concentration (MTAC), MCC = minimum cysticidal concentration, MCT = 635 
minimum cytotoxic concentration.
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Table 2. Efficacy of topical antibiotics, antivirals and preservatives against Acanthamoeba 653 
spp. trophozoites and cysts, and toxicity to a human epithelial cell line (Hep2). 654 
In vitro drug sensitivities (µg/ml) 
Drug 
A. castellanii A. polyphaga Hep2 
MTIC MTAC MCC MTIC MTAC MCC MCT 
 
†
Levofloxacin (Oftaquix
®
) 78 156 625 156 312 625 39 
Levofloxacin (Pure drug) 312 1250 2500 625 1250 5000 78 
Moxifloxacin (Moxeza
®
) 625 2500 2500 1250 2500 2500 156 
Chloramphenicol (Pure 
drug) 
312 625 2500 312 625 1250 625 
†††
Chloramphenicol (Generic) 78 312 625 39 156 312 312 
Aciclovir (Pure Drug) 63 125 >500 125 250 >500 31.3 
††
Trifluorothymidine 312 625 5000 625 1250 2500 156 
Benzalkonium Chloride 3.9 7.8 15.6 1 1.95 7.8 31.3 
Phenylmercuric Nitrate 1.95 3.9 31.3 1 1.95 15.6 3.9 
MTIC = minimum trophozoite inhibitory concentration, MTAC = minimum trophozoite 655 
amoebicidal concentration, MCC = minimum cysticidal concentration, MCT = minimum 656 
cytotoxic concentration.
 † 
Compound is preserved with benzalkonium chloride (0.005% w/v), 657 
†† 
compound is preserved with benzalkonium chloride (0.02% w/v), 
††† 
Compound is 658 
preserved with phenylmercuric nitrate (0.002% w/v). 659 
 660 
 661 
 662 
 663 
 664 
 665 
 666 
Table 3. Efficacy of diamidine compounds against Acanthamoeba spp.  trophozoites and 667 
cysts, and toxicity to a human epithelial cell line (Hep2). 668 
In vitro drug sensitivities (µg/ml) 
Drug 
A. castellanii A. polyphaga Hep2 
MTIC MTAC MCC MTIC MTAC MCC MCT 
Propamidine (Pure drug) 62.3 250 >500 250 500 >500 250 
†
Propamidine (Brolene®) 7.8 15.6 500 15.6 31.3 250 31.3 
Hexamidine (Pure drug)  7.8 62.3 250 7.8 31.3 250 62.3 
Hexamidine (Desomedine®) 7.8 62.3 250 7.8 31.3 250 62.3 
Pentamidine (Pure drug) 62.3 250 >500 125 250 >500 125 
MTIC = minimum trophozoite inhibitory concentration, MTAC = minimum trophozoite 669 
amoebicidal concentration, MCC = minimum cysticidal concentration, MCT = minimum 670 
cytotoxic concentration. 
† 
Compound is preserved with benzalkonium chloride (0.005% w/v). 671 
 672 
 673 
 674 
 675 
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 677 
 678 
 679 
 680 
 681 
 682 
 683 
 684 
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 688 
Table 4. Efficacy of biguanides and povidone iodine compounds against Acanthamoeba spp. 689 
for trophozoites and cysts and toxicity to a human epithelial cell line (Hep2). 690 
In vitro drug sensitivities (µg/ml) 
 
Drug 
A. castellanii A. polyphaga Hep2 
MTIC MTAC MCC MTIC MTAC MCC MCT 
Polyhexamethylene Biguanide 1 3.9 15.6 1 7.8 7.8 31.3 
Chlorhexidine 1 3.9 31.3 1.95 15.6 31.3 3.9 
Octenidine 1 1.95 7.8 0.5 1 3.9 1.95 
Alexidine 1 1.95 3.9 1.95 7.8 7.8 1 
Povidone iodine 7.8 31.3 15.6 7.8 31.3 7.8 125 
MTIC = minimum trophozoite inhibitory concentration, MTAC = minimum trophozoite 691 
amoebicidal concentration, MCC = minimum cysticidal concentration, MCT = minimum 692 
cytotoxic concentration. 693 
 694 
 695 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Transmission electron microscopy images of Acanthamoeba cyst after 1 hour 
exposure to the following 7 agents: (A) untreated healthy cyst as control; (B) treated with 1% 
tetracaine; (C) treated with 0.5% preserved chloramphenicol; (D) treated with 0.1% 
propamidine pure drug; (E) treated with 0.05 mg/ml benzalkonium chloride; (F) treated with 
5% povidone iodine; (G) treated with 0.02% PHMB; (H) treated with 0.5% unpreserved 
chloramphenicol. Bar = 2 µm. 
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